within Pharmacolibrary.Drugs.ATC.R;

model R01AD11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.46,
    Cl             = 28 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 220 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Triamcinolone is a synthetic corticosteroid used primarily for its anti-inflammatory and immunosuppressive properties. It is used in various forms (oral, injectable, topical, and intranasal) to treat conditions such as allergic rhinitis, asthma, arthritis, and dermatological disorders. The intranasal formulation (ATC code R01AD11) is commonly approved and used today for the symptomatic relief of nasal allergy, such as hay fever.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for intranasal administration in healthy adults, as no direct human PK data for intranasal triamcinolone is reported. Parameters are based on literature for similar corticosteroids and general knowledge of triamcinolone's pharmacology.</p><h4>References</h4><ol><li><p>Szefler, SJ (2001). Pharmacokinetics of intranasal corticosteroids. <i>The Journal of allergy and clinical immunology</i> 108(1 Suppl) S26–S31. DOI:<a href=&quot;https://doi.org/10.1067/mai.2001.115563&quot;>10.1067/mai.2001.115563</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11449203/&quot;>https://pubmed.ncbi.nlm.nih.gov/11449203</a></p></li><li><p>Gawchik, SM, &amp; Saccar, CL (2000). A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. <i>Drug safety</i> 23(4) 309–322. DOI:<a href=&quot;https://doi.org/10.2165/00002018-200023040-00004&quot;>10.2165/00002018-200023040-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11051218/&quot;>https://pubmed.ncbi.nlm.nih.gov/11051218</a></p></li><li><p>Naclerio, RM (1998). Optimizing treatment options. <i>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</i> 28 Suppl 6 54–59. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2222.1998.0280s6054.x&quot;>10.1046/j.1365-2222.1998.0280s6054.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9988437/&quot;>https://pubmed.ncbi.nlm.nih.gov/9988437</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R01AD11;
